Compare CMCO & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCO | RZLT |
|---|---|---|
| Founded | 1875 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.1M | 420.8M |
| IPO Year | 2002 | 2011 |
| Metric | CMCO | RZLT |
|---|---|---|
| Price | $20.15 | $4.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $21.00 | $9.67 |
| AVG Volume (30 Days) | 763.9K | ★ 1.3M |
| Earning Date | 05-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $936,240,000.00 | N/A |
| Revenue This Year | $19.73 | N/A |
| Revenue Next Year | $82.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.27 | N/A |
| 52 Week Low | $11.99 | $1.07 |
| 52 Week High | $24.40 | $11.46 |
| Indicator | CMCO | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 66.43 | 48.32 |
| Support Level | $20.49 | $2.91 |
| Resistance Level | $21.58 | $4.71 |
| Average True Range (ATR) | 1.27 | 0.35 |
| MACD | 0.62 | -0.04 |
| Stochastic Oscillator | 81.35 | 30.50 |
Columbus McKinnon Corp is a world'wide designer, manufacturer and marketer of intelligent motion solutions for material handling that move the world forward and improve lives by efficiently and ergonomically moving, lifting, positioning and securing materials. Key products include hoists, crane components, precision conveyor systems, rigging tools, light rail workstations and digital power and motion control systems. These are relevant, professional-grade solutions that solve its customers critical material handling requirements.The Company has one operating and reportable segment. It has presence in United State, Germany, Europe, Middle East, and Africa (Excluding Germany), Canada, Asia Pacific, and Latin America. It has majority of sales from United States.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.